Riskpilot← Back to searchSign inGet full accessVISTIN PHARMA ASA
ASAActiveOrg 915157882Østensjøveien 27, 0661 OsloManufacture of pharmaceutical preparations · NACE 2120Est. 20150 employeeswww.vistin.com
Revenue 2024
NOK 0
EBITDA margin
—
+13% vs 2023
Equity ratio
98.6%
Financial strength
Net profit 2024
NOK -3,5M
-18% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -6,1M | +13% |
| Net profit | NOK -3,5M | -18% |
| Total assets | NOK 186,6M | -30% |
| Equity | NOK 184M | -31% |
| Employees | 0 | — |
Legal name
VISTIN PHARMA ASA
Org number
915157882
Legal form
Allmennaksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
24. mars 2015
Share capital
NOK 44 344 592
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskapets underskrift innehas av styreformann eller to av styrets medlemmer samlet. Styret kan gi prokura.
Company purpose
Utvikling, produksjon og salg av legemidler og andre helserelaterte produkter og tjenester. Dette kan også realiseres ved eierskap i andre selskaper.
Address
Østensjøveien 27, 0661 Oslo
Website
www.vistin.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −1 740 | −1 947 | −1 962 | −2 147 | −3 697 |
| EBITDA | −2 822 | −4 698 | −4 194 | −6 978 | −6 052 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −2 822 | −4 698 | −4 194 | −6 978 | −6 052 |
| Net financials | 3 096 | 1 419 | 1 820 | 3 152 | 1 532 |
| Profit before tax | 274 | −3 279 | −2 374 | −3 826 | −4 520 |
| Tax | 60 | −721 | −522 | −842 | −994 |
| Net profit | 214 | −2 558 | −1 852 | −2 984 | −3 526 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 295 649 | 277 810 | 269 084 | 266 244 | 186 589 |
| Equity | 294 713 | 269 983 | 268 132 | 265 148 | 184 035 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 937 | 7 829 | 953 | 1 096 | 2 554 |
| Total debt | 937 | 7 829 | 953 | 1 096 | 2 554 |
EBITDA margin
-605200000.0%
This company
15.8%
Market median
-3830379847% vs market
20202024
Equity ratio
98.6%
This company
38.2%
Market median
+158% vs market
20202024
Return on equity
-1.9%
This company
18.4%
Market median
-110% vs market
20202024
Net profit margin
-352600000.0%
This company
8.1%
Market median
-4353086520% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (10) | ||
KE Observer | Observer | 2024 |
MW Chief Executive Officer | Chief Executive Officer | 2023 |
AK Deputy Member | Deputy Member | 2025 |
ET Deputy Member | Deputy Member | 2021 |
SI Deputy Member | Deputy Member | 2025 |
SJ Deputy Member | Deputy Member | 2023 |
KP Deputy Member | Deputy Member | 2025 |
SS Deputy Member | Deputy Member | 2023 |
PS Deputy Member | Deputy Member | 2021 |
GA Deputy Member | Deputy Member | 2025 |
| Former (3) | ||
KM Deputy Member | Deputy Member | 2021 – 2023 |
FI Deputy Member | Deputy Member | 2020 – 2021 |
BS Deputy Member | Deputy Member | 2021 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 28.36% | 28.36% | 2024 | |
| Company | 9.47% | 9.47% | 2024 | |
| Company | 6.75% | 6.75% | 2024 | |
| Company | 3.88% | 3.88% | 2024 | |
| Company | 2.78% | 2.78% | 2024 | |
| Company | 1.69% | 1.69% | 2024 | |
| Company | 1.69% | 1.69% | 2024 | |
| Company | 1.62% | 1.62% | 2024 | |
| Individual | 1.59% | 1.59% | 2024 | |
| Company | 1.58% | 1.58% | 2024 | |
| Individual | 1.45% | 1.45% | 2022 | |
| Company | 1.22% | 1.22% | 2024 | |
| Company | 1.22% | 1.22% | 2024 | |
| Company | 1.19% | 1.19% | 2024 | |
| Individual | 1.17% | 1.17% | 2024 | |
| Individual | 1.16% | 1.16% | 2022 | |
| Company | 1.15% | 1.15% | 2024 | |
| Company | 1.13% | 1.13% | 2024 | |
Dnb Bank Asa | Company | 1.13% | 1.13% | 2024 |
| Company | 1.03% | 1.03% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kongskilen As
VISTIN PHARMA ASA Board members of VISTIN PHARMA ASA also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjell Erik Nordby | Observer | 0 companies |
| Magnus Wilhelm Tolleshaug | Chief Executive Officer | 0 companies |
| Arve Kristensen | Deputy Member | 0 companies |
| Erle Tufte | Deputy Member | 0 companies |
| Kjellaug Marit Danielsen | Deputy Member | 0 companies |
| Frode Iversen | Deputy Member | 0 companies |
| Stig Isaksen | Deputy Member | 0 companies |
| Bengt Sveen | Deputy Member | 0 companies |
| Stian Johnsen | Deputy Member | 0 companies |
| Kristine Pedersen | Deputy Member | 0 companies |
| Susanne Sørdalen | Deputy Member | 0 companies |
| Petter Sørdalen | Deputy Member | 0 companies |
| Guro Amalie Øyløkken | Deputy Member | 0 companies |
| Øystein Stray Spetalen | Board of Directors | 0 companies |
| Øyvin Anders Brøymer | Chairman | 0 companies |
| Bettina Banoun | Board of Directors | 0 companies |
| Åse Musum | Board of Directors | 0 companies |
| Stine Wang Rønningen | Board of Directors | 0 companies |
| Kari Eian Krogstad | Board of Directors | 0 companies |
| Espen Weyergang Marcussen | Board of Directors | 0 companies |
| Espen Lia Gregoriussen | Board of Directors | 0 companies |